ORIC PHARMACEUTICALS INC (ORIC) Stock News

USA - NASDAQ:ORIC - US68622P1093 - Common Stock

12.815 USD

+0.35 (+2.85%)

Last: 11/11/2025, 12:49:06 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ORIC Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4 days ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

5 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

7 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

7 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

15 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

15 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

2 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

3 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Zacks Investment Research

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

5 months ago - By: Yahoo Finance - Mentions: AMZN PLTR WMT COST ...

Palantir Stock vs. Amazon Stock: Wall Street Says Buy One and Sell the Other

5 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Zacks Investment Research

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know

6 months ago - By: Stocktwits

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial

6 months ago - By: Yahoo Finance - Mentions: NPCE IVVD ENPH HOWL ...

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

6 months ago - By: Yahoo Finance - Mentions: IVVD NPCE HOWL THC ...

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

6 months ago - By: Benzinga - Mentions: STRM BBY CAL REVB ...

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results

6 months ago - By: Zacks Investment Research - Mentions: JNJ AMRN

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

6 months ago - By: Benzinga

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

6 months ago - By: Yahoo Finance - Mentions: NVDA SEDG FLNC

Morning Bid: Markets hope Trump tariffs stay 'unlawful'